ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0685

Characteristics and Outcome of AKI Needing Dialysis with COVID-19 Infection

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Sankarasubbaiyan, Suresh, Nephroplus, Hyerabad, Telengana, India
  • Gowda, Mallikarjuna Gowda Bg, Nephroplus, Hyerabad, Telengana, India
  • Ganapathi Subraman, Venkatraman, Nephroplus, Hyerabad, Telengana, India
  • Husain, Mohammad Sarwar, Nephroplus, Hyerabad, Telengana, India
  • Sonawane, Vikram Ashok, Nephroplus, Hyerabad, Telengana, India
  • Puvvada, Satyanarayana Rajesh, Nephroplus, Hyerabad, Telengana, India
  • Kumar, Kaparaboina Kartheek, Nephroplus, Hyerabad, Telengana, India
  • Venkata, Guruvulu, Nephroplus, Hyerabad, Telengana, India
  • Shah, Kamal D., Nephroplus, Hyerabad, Telengana, India
Background

COVID-19 infection has varying grades of mortality worldwide. Multi-organ injury, not uncommonly associated with AKI, portends a poor outcome. We studied AKI needing hemodialysis (HD) in the context of COVID-19 infection

Methods

From March 15th to May 25th 2020, for consecutive COVID-19 infections AKI needing HD in a large dialysis network age, gender, payer type, days:admission to HD start, urine output, S. Cr, comorbidities, other organ injuries, length of stay & outcome , dialysis session details: blood flow rate(BFR), dialysis flow rate(DFR), ultafiltration volume were reviewed. We compared survivors and non survivors using Mann Whitney/Wilcoxon 2 sample test for medians and Fisher exact 2 tailed for association

Results

n = 20. Mean age: 56. 7 + 3.93 years. M:F 17:3, 9 survived, 11 expired. HD sessions=51; CRRT: 4, duration: 29.2 + 25.4 hours. 47 sessions: Duration: 4.87 + 1.11 hours, BFR: 195 + 43 ml/min, DFR: 389 +99 ml/mn, UF: 437ml/hour. No clotting reported.

Conclusion

AKI needing HD in COVID-19 infection is associated with significant multiorgan injury and high mortality; middle aged male predominate. No significant clinical characteristics were predictive of survival in a sample size

Comparison of survivors and non survivors of COVID-AKI needing HD
 Survivors (n= 9)Non survivors (n=11)p value
Age (yrs)56550.68
M/F (%)88.9/11/.181.8/18.21.0
Self pay or private Insurance/public Insurance (%)77.7/22.281.8/18.2 
Htn (%)33.327.31.0
DM (%)11.136.4.31
Altered Mentation88.9%63.6.32
Vasopressor use (%)22.245.5.37
Ventilator (%)47.3752.631.0
Admission to HD start interval (days)210.87
Oliguria (%)88.990.91.0
S. Creatinine (mg%)6.163.000.09
No of HD220.65
Hb (g%)9.610.8.17
TC (/MM3)9878 ± 495023962 ± 22221 
Hospital stay (days)2413.60
Antivirals Rx (%)66.7%90.9%.28
Steroid Rx (%)66.7%81.8%.61